On October 22, 2025, Elevara Medicines (Elevara), a clinical-stage biotech developing therapies for rheumatoid arthritis and chronic inflammatory diseases, announced the close of a $70 million Series A financing. The round was co-led by Forbion and Sofinnova Partners, with participation from founding investor Monograph Capital. Wilson Sonsini Goodrich & Rosati advised Elevara on IP matters related to the transaction.

The Series A proceeds will fund Elevara’s upcoming Phase 2 clinical trial of its lead candidate ELV001 and support exploratory programs in additional chronic inflammatory conditions and women’s health. The START-SYNERGY Phase 2 trial will enroll approximately 180 patients with inadequate response to methotrexate and TNF inhibitors, with recruitment expected to begin before the end of 2025.

The Wilson Sonsini team that advised Elevara on IP matters related to this transaction includes Lou Lieto, Michael Hostetler, Ying Chen, and Heng Zhang.

For more information, please see Elevara’s news release.